Introduction
============

Cardiovascular disease (CVD) is a well-known complication of diabetes mellitus (DM), and patients with DM are at an increased risk for early onset of CVD. It is evident that atherosclerosis begins in childhood (Berenson et al., [@B6]; Strong et al., [@B44]); however, CVD risk factors are most frequently assessed in the adult population. A cross-sectional analysis of the German diabetes documentation and quality management system (DPV) showed that of the 33,488 pediatric patients with type 1 diabetes (T1D) in the system between September 2007 and September 2008, only 26% had no additional risk factors for CVD \[Hemoglobin A1c (HbA1c) ≥7.5%, hypertension, dyslipidemia, obesity, and smoking\], 39% had one risk factor, and 35% had two or more (Schwab et al., [@B40])!

Studies have shown that adults with T1D diagnosed in childhood develop more advanced atherosclerosis earlier in life than the general population (Valsania et al., [@B47]) and have a higher rate of cardiac failure (Savage and Semple, [@B39]) and shorter survival (Portuese and Orchard, [@B34]). The primary mediator in atherosclerosis for patients with T1D is hyperglycemia (Kavey et al., [@B22]). Optimizing glycemic control in patients with DM is generally accepted as the foundation for improving CVD risk; however, the approach to dyslipidemia treatment in the setting of optimal glycemic control is less clear.

With the rise in obesity, insulin resistance, and type 2 diabetes (T2D) in youth, increasing evidence suggests that these patients may be at an even greater risk for CVD than similar aged adolescents with T1D (Wadwa, [@B49]). Insulin resistance contributes to dyslipidemia as both hepatic synthesis of very-low-density lipoprotein (VLDL-C) is enhanced and peripheral action of lipoprotein lipase is decreased, leading to increases in low-density lipoprotein (LDL-C) and triglyceride (TG) levels (Kavey et al., [@B22]; Savage and Semple, [@B39]). These derangements as well as low HDL-C levels have been shown to correlate with the degree of atherosclerosis in children (NCEP Expert Panel on Blood Cholesterol Levels in Children and Adolescents, [@B32]).

Much research has been done to identify biomarkers and non-invasive radiological findings that suggest either existing CVD or CVD risk. While measurements such as carotid intima media thickness (cIMT) and C-reactive protein (CRP) are used as markers of CVD in adults, their utility in pediatrics is debatable. Beyond the use of these studies in the research field, their role in pediatric clinical practice has not been established.

Current Cholesterol Guidelines
==============================

Many guidelines have been developed to help clinicians manage patients with DM and dyslipidemia (see Table [1](#T1){ref-type="table"}). In this age of evidence-based medicine, it is disappointing that the recommendations must be frequently based on individual expert opinions and clinical experience. Researchers have had difficulty obtaining prospective longitudinal data and experimenting with drugs and interventions in children, thereby limiting the evidence available.

###### 

**Cholesterol guidelines overview\***.

                                       NCEP Expert Panel on Blood Cholesterol Levels in Children, (1992)                                                   AAP, (2008)^†^                                                                 ADA (2003, 2005,^‡^ 2010, 2011)                                                                                                                                                                                                                                                                                                                                                ISPAD, (2009)^§^                                                                                                                                                      AHA, (2006)^\|\|^
  ------------------------------------ ------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  Initial screen type 1 diabetes       Not addressed                                                                                                       Not addressed                                                                  Patients \>2 years age with positive or unknown family history: soon after diagnosis after establishing glycemic control. If negative family history: puberty or 10 years age (2011, 2010).                                                                                                                                                                                    Patients \>2 years age with positive or unknown family history: soon after diagnosis after establishing glycemic control. If negative family history: 12 years age.   Not addressed
  Screening interval type 1 diabetes   Not addressed                                                                                                       Not addressed                                                                  If normal, every 5 years (2011, 2010); if abnormal, yearly (2011). If treated with pharmacotherapy, repeat FLP in 3 and 6 months then annually (2003).                                                                                                                                                                                                                         If normal, every 5 years.                                                                                                                                             Not addressed
  Initial screen type 2 diabetes       Not addressed                                                                                                       Not addressed                                                                  After establishing glycemic control (2010, 2011).                                                                                                                                                                                                                                                                                                                              Not addressed                                                                                                                                                         Not addressed
  Screening interval type 2 diabetes   Not addressed                                                                                                       Not addressed                                                                  If normal, every 5 years; if abnormal, yearly (2010, 2011). If normal, every 2 years (2003). If treated with pharmacotherapy, repeat FLP in 3 and 6 months then annually (2003).                                                                                                                                                                                               Not addressed                                                                                                                                                         Not addressed
  Target                               LDL-C \<110 mg/dL                                                                                                   LDL-C \<130 mg/dL                                                              LDL-C \<100 mg/dL (2010, 2011), HDL-C \>35 mg/dL, TG \<150 mg/dL (2003).                                                                                                                                                                                                                                                                                                       Not addressed                                                                                                                                                         LDL-C ≤100 for T1D and high-risk T2D. LDL-C ≤130 in low risk T2D.
  Recommended therapy                  Step-one diet × 3 months. If not at target, proceed to Step-two diet. If not at target, consider medical therapy.   Step-two diet. If not at target, consider pharmacotherapy if \>10 years age.   If LDL-C elevated, optimize glycemic control and initiate Step-two diet. If LDL-C is not lower than 160 or 130 mg/dL in patients with additional risk, then initiate statin (2010, 2011) at the lowest dose and titrate as needed to achieve target. If TG elevated, optimize glucose control, weight loss if needed, and fibric acid medication if TG \>1,000 mg/dL (2003).   Not addressed                                                                                                                                                         Step-two diet and avoid trans fats × 6 months. If not at target, consider statin use if ≥10 years age.
  Adverse effect monitoring            Not addressed                                                                                                       Not addressed                                                                  LFTs, symptoms of muscle pain (2003), risk of statin use in pregnancy (2005).                                                                                                                                                                                                                                                                                                  Symptoms of muscle pain                                                                                                                                               Not addressed

*\*Guidelines are listed in the order of which they were discussed in the text. The order does not indicate author preference. ^†^Daniels et al. ([@B10]). ^‡^Silverstein et al. ([@B42]). ^§^Donaghue et al. ([@B13]). ^\|\|^Kavey et al. ([@B22])*.

In 1992, the National Cholesterol Education Program (NCEP) published guidelines for approaching dyslipidemia in children; however, dyslipidemia management specifically in patients with DM is not addressed. These guidelines describe a two-step dietary approach for elevated LDL-C treatment prior to medical therapy. Step-one of this approach entails a low fat diet (≤30% of total calories from total fat, \<10% of total calories from saturated fatty acids, ≤ of total calories from polyunsaturated fatty acids), \<300 mg/day of cholesterol, carbohydrates accounting for 55% of total calories, and protein accounting for 15--20% of total calories. Patients should practice this step-one diet for 3 months. If the patients do not achieve target LDL-C levels of \<110 mg/dL, then patients should proceed to the step-two diet, in which saturated fatty acids now comprise \<7% of total calories and cholesterol is limited to \<200 mg/day (NCEP Expert Panel on Blood Cholesterol Levels in Children and Adolescents, [@B32]).

The Dietary Intervention Study in Children demonstrated that after 3 years of follow-up, there was a significant difference in LDL-C levels after implementing a step-two diet compared to the usual care group with no adverse effects on growth and development (Kwiterovich, [@B23]). If LDL-C levels are not at target after practicing step-two of the dietary changes, then medical therapy should be considered in children aged ≥10 years with LDL-C ≥190 mg/dL or LDL-C \>160 mg/dL with either a positive family history of CVD before age 55 years or presence of ≥2 risk factors (cigaret smoking, hypertension, HDL-C \<35 mg/dL, body mass index (BMI) ≥95% percentile, DM, and physical inactivity; NCEP Expert Panel on Blood Cholesterol Levels in Children and Adolescents, [@B32]). The 2008 American Academy of Pediatrics guidelines entitled "Lipid Screening and Cardiovascular Health in Childhood" recommended consideration of pharmacotherapy in patients with DM and LDL-C ≥130 mg/dL if ≥10 years of age or older (Daniels et al., [@B10]).

According to the 2010 and 2011 American Diabetes Association (ADA) "Standards of Medical Care in Diabetes," patients with T1D who are \>2 years of age with a family history of hypercholesterolemia \[total cholesterol (TC) \>240 mg/dL\], a cardiovascular event before age 55 years, or unknown family history should be screened with a fasting lipid profile (FLP) soon after diagnosis and glycemic control has been achieved. If family history is not concerning, then lipid screening should begin at puberty or ≥10 years of age. If DM diagnosis occurs after puberty, then a FLP should be performed after establishing glycemic control. If LDL-C levels are \<100 mg/dL, then the lipid profile should be repeated every 5 years (American Diabetes Association, [@B2], [@B3]). According to the 2011 guidelines, if the profile is abnormal, it should be repeated yearly (American Diabetes Association, [@B3]). However, it is not clear if this screening interval is different for patients treated with cholesterol-lowering medications. In patients with T2D, FLP should be obtained at the time of diagnosis. After diagnosis of T2D, both ADA standards state that guidelines are "similar to those for youth with type 1 diabetes," suggesting that screening occur after establishing glycemic control then every 5 years if LDL-C is \<100 mg/dL or every 1 year if LDL-C is \>100 mg/dL (American Diabetes Association, [@B2], [@B3]). These 2010 and 2011 standards differ somewhat from the ADA's 2003 consensus statement on "Management of Dyslipidemia in Children and Adolescents with Diabetes." Previously, the recommended screening interval in patients with T2D with normal lipid profiles was every 2 years (American Diabetes Association, [@B1]). With the high prevalence of comorbidities in patients with T2D and the insidious nature of symptom--onset leading to possibly years prior to diagnosis, it seems that the more frequent monitoring of lipid profiles would be favored.

For patients diagnosed with dyslipidemia from FLPs, the initial recommended therapy according to the 2010 and 2011 ADA guidelines should include optimizing glycemic control and using step-two of the NCEP diet as described above. After 10 years of age, if lifestyle changes have not lowered the LDL-C to ≤160 or ≤130 mg/dL in patients with additional CVD risk factors, then a statin is recommended for therapy to achieve a LDL-C of \<100 mg/dL (American Diabetes Association, [@B2], [@B3]). The ADA recommended that statins should be started at the lowest dose available and titrated up as needed. Periodic monitoring of liver function tests (LFTs) is necessary in statin use, and medications should be stopped if LFTs exceed three times the upper limit of normal. Statins should also be discontinued if persistent muscle pain occurs, but routine creatinine phosphokinase monitoring was not felt to be helpful (American Diabetes Association, [@B1]).

Though the Lovastatin in Adolescent Male study has shown statins to decrease LDL-C levels without adverse effects on growth and development in adolescent males over 7 years when compared to usual care, the ADA has recognized that long-term safety and efficacy data is not available (Kwiterovich, [@B23]; American Diabetes Association, [@B2], [@B3]). In the 2005 guidelines entitled "Care of Children and Adolescents with Type 1 Diabetes" the ADA also raised concerns about the use of statins in sexually active females as these drugs are not approved in pregnant individuals (Silverstein et al., [@B42]).

The 2003 statement further describes optimal HDL-C levels of \>35 mg/dL and TG levels \<150 mg/dL. Elevated TG levels should be treated by optimizing glucose control, weight loss if needed, and using fibric acid medication if TG levels ≥1,000 mg/dL. For patients on medical treatment for dyslipidemia, the ADA recommends repeating a FLP 3 and 6 months after therapy initiation, and then annually once treatment goals are achieved (American Diabetes Association, [@B1]).

The International Society for Pediatric and Adolescent Diabetes published clinical practice guidelines in 2009 similar to the ADA guidelines from 2010 to 2011 with the exception that initial lipid screening in patients without a family history of CVD and without additional risk factors should begin at age 12 years. The recommended interventions for dyslipidemia included improvement of glycemic control and statin use. The authors also recognized that long-term safety of statins has not yet been established (Donaghue et al., [@B13]).

In the 2006 scientific statement regarding CVD risk reduction in high-risk pediatric patients, the American Heart Association (AHA) identified T1D and T2D as one of eight conditions at risk for premature atherosclerosis beginning in childhood. The evidence for early coronary disease further stratified T1D as part of the high-risk tier I category and T2D as part of the moderate risk tier II category. However, patients with T2D are usually classified as high risk in tier I because of the presence of at least two other comorbidities (dyslipidemia, smoking, CVD ≤55 years of age for first degree male relatives and ≤65 years of age for first degree female relatives, hypertension, overweight/obese, physically inactive). Children within tier I should be approached as having a "coronary heart disease equivalent." The AHA recommends that those patients in the tier 1 category obtain LDL-C ≤ 100 mg/dL and those within the tier II category obtain LDL-C ≤ 130 mg/dL. In order to reach these cholesterol levels, the first recommended step is to initiate the NCEP step-two diet under the guidance of a nutritionist with the addition of avoidance of trans fats for 6 months. If LDL-C goals are not achieved, then statin therapy should be considered if the child is older than 10 years of age (Kavey et al., [@B22]). The AHA guidelines were endorsed by the American Academy of Pediatrics.

Aside from the 2003 ADA consensus statement that addresses hypertriglyceridemia, there are no other official guidelines for the approach to TG or HDL-C management. The Pittsburgh Epidemiology of Diabetes Complications Study evaluated 10 years of mortality and morbidity data related to T1D. In this study of nearly 600 patients, risk ratios were calculated between cholesterol levels and mortality, coronary artery disease, and overt nephropathy. Based on risk ratios of at least 1.8, the following cholesterol goal levels were recommended by the researchers: LDL-C \<100 mg/dL, HDL-C \>45 mg/dL, TG \<150 mg/dL (Orchard et al., [@B33]).

Recent studies have suggested that additional lipid parameters may be useful in the assessment and management of youth with DM. The SEARCH for Diabetes in Youth study found an association between glycemic control and fasting lipid concentrations in subjects with T1D, as those with a HbA1c \<7.5% had similar TC and LDL-C levels but lower TG and higher HDL-C levels compared to healthy controls, while the patients with HbA1c ≥7.5% had elevated TC, LDL-C, non-HDL-C, and HDL-C levels. Interestingly, the subjects with DM (even those in optimal control) had significantly higher apolipoprotein B (Apo B) and a greater number of small dense LDL-C particles than the control subjects, suggesting that the lipids in patients with DM in some ways may be more atherogenic. Small dense LDL-C, which contains less cholesterol per particle and tends to become oxidized, has been shown to be an independent predictor of CVD (Guy et al., [@B16]). In patients with DM, LDL-C particle number may be higher at any given LDL-C concentration, likely because of the increased percentage of small dense LDL-C particles (Vijayaraghavan, [@B48]). Apo B has also been shown to be an independent predictor of CVD and may provide a better estimate of LDL-C particle number than LDL-C or non-HDL-C in patients with insulin resistance and DM (Ganda, [@B15]). Therefore, it may be useful for future guidelines to incorporate other lipid parameters as additional goals of therapy. Overall, it appears that there are both gaps and discrepancies among the different clinical guidelines, making it difficult for providers who are seeking specific guidelines for their patients with DM.

Cost of Dyslipidemia
====================

The incidence rates of both T1D and T2D are rising, and with them the burden of their complications. As with much other data in pediatric DM, cost-analysis data does not exist for the treatment of dyslipidemia beginning in childhood. Adult literature shows that several European cost-effectiveness studies based on the "Collaborative Atorvastatin Diabetes Study" have determined atorvastatin use in adults to be cost--effective to various degrees depending on the country in which the drug is to be used when compared to no treatment in the prevention of CVD (Raikou et al., [@B36]; Lafuma et al., [@B24]; Annemans et al., [@B4]).

A systematic review of interventions in adults for preventing and controlling DM demonstrated that statin use was "very cost--effective" in the secondary prevention of CVD, while those strategies described as "cost--effective" included the primary prevention of CVD for patients with T2D and hyperlipidemia, intensive insulin treatment for people with T1D compared with conventional glycemic control, and intensive glycemic control by a Diabetes Prevention Program type of intensive lifestyle intervention (ILI) in people with newly diagnosed T2D compared with conventional glycemic control. Surprisingly, intensive glycemic control for all U.S. residents with T2D diagnosed at age ≥25 years compared with usual care was only "marginally cost--effective" (Li et al., [@B25]). One would presume that glycemic control would be the most cost--effective since it is considered to be the cornerstone of dyslipidemia treatment. The AHEAD study examined the cost-savings of an ILI regimen compared to a DM support and education system in adults with T2D. In this study, the ILI group improved their lipid profiles, decreased medication use, and saved \$40 per month in medication costs (Redmon et al., [@B37]).

Other CVD Risk Markers
======================

Other biomarkers and radiologic testing are frequently performed for research purposes to better understand the pathophysiological course of CVD, but what is the role of this testing in routine clinical practice? Before implementing these tests into routine care, normative values must be established in the healthy pediatric population for each of these tests.

Carotid intima media thickness has been used in the adult population to assess the degree of CVD risk due to atherosclerosis. This practice is based on studies suggesting that cIMT correlates with risk of cardiovascular events (de Groot et al., [@B11]). One longitudinal study of patients with T1D over a 2-year period showed that of the patients who had an elevated cIMT at baseline, those who had worsening of cIMT also had a higher HbA1c, though there were no significant differences in lipid profile, systolic blood pressure, or BMI measurements (Dalla Pozza et al., [@B9]). Although studies have also revealed a thicker cIMT in patients with T1D compared to those without DM, conflicting data exists regarding whether cIMT is associated with DM duration (Atabek et al., [@B5]; Dalla Pozza et al., [@B8]; Rabago Rodriguez et al., [@B35]; Margeirsdottir et al., [@B28]).

One study from the International Childhood Cardiovascular Cohort (iC3) Consortium examined the association in healthy subjects between cholesterol, BMI, and systolic blood pressure among different childhood age groups and cIMT in adulthood. This study showed that TC level was associated with cIMT in adulthood beginning at age 12, systolic blood pressure was associated with cIMT beginning at age 6, and BMI was associated with cIMT beginning at age 9 (Juonala et al., [@B21], [@B20]). A similar study using data from the Bogalusa Heart Study, Young Finns Study, and Childhood Determinants of Adult Health Study found that adolescents with elevated LDL-C had an increased risk of high cIMT if LDL-C did not normalize by adulthood. Both groups with persistent low HDL-C and with low HDL-C that normalized by adulthood had an increased risk of high cIMT (Magnussen et al., [@B27]). While these CVD risk factors in children predict cIMT in adulthood, what does cIMT in childhood indicate? Furthermore, to what extent are cIMT derangements found in childhood reversible through early interventions?

Many studies have examined the normative values for cIMT in healthy children. Some studies suggest that cIMT is positively associated with age (Ishizu et al., [@B18]; Bohm et al., [@B7]), while other studies do not find this association (Sass et al., [@B38]). Gender differences were appreciated in one major study by Bohm et al. ([@B7]), but not found in another large study in a similar population (Jourdan et al., [@B19]). Clearly there is disagreement in cIMT measurements even in similar populations and none of the standards proposed would be generalizable to a clinic with patients of mixed ethnic and racial backgrounds. It is also likely that cIMT methods vary across institutions and may be evaluator-dependent.

Other radiologic measures for assessing vascular function include arterial compliance, stiffness, and distensibility. Two studies (one adult, one pediatric) have shown that patients with T1D have lower arterial compliance and distensibility when compared to healthy controls; nevertheless, exercise was shown to improve these measures in both groups, but not to the same levels as healthy controls (Mason et al., [@B29]; Trigona et al., [@B45]). Although some evidence suggests that patients with T1D have reduced arterial compliance and distensibility as well as increased arterial stiffness, some studies disagree (Galler et al., [@B14]; Margeirsdottir et al., [@B28]). A scientific statement by the AHA in 2009 regarding the use of measurements of cIMT, coronary artery calcification by computed tomography, arterial stiffness, arterial distensibility, and arterial dilation concluded that "Additional data are needed before these methods can be adopted in clinical evaluation" (Urbina et al., [@B46]).

Many researchers focus on the role of inflammation in CVD development. Pediatric patients with T1D have been shown to have increased inflammatory markers even with acceptable glycemic control (Snell-Bergeon et al., [@B43]). In two studies of children and young adults with T1D, elevated serum levels of inflammatory markers such as CRP were associated with higher cIMT measurements, suggesting an increased risk of CVD (Hayaishi-Okano et al., [@B17]; Atabek et al., [@B5]). However, another study showed that while CRP in childhood was weakly associated with CRP levels in adulthood, it was not associated with cIMT in adulthood (Juonala et al., [@B21]). It is important to note that standard CRP normative ranges are generally not reported in the pediatric population (McNeal et al., [@B30]).

A recent study showed that inflammatory markers such as IL-6 and fibrinogen were elevated in youth with T1D, regardless of their weight status or glycemic control. High sensitivity CRP (hs-CRP) was also found to be higher in the patients with worsening glycemic control. Moreover, elevations in these inflammatory markers were associated with a more atherogenic lipid profile (higher TC, LDL-C, and Apo B, but lower HDL-C; Snell-Bergeon et al., [@B43]). Other biomarkers that reflect endothelial cell dysfunction have been studied very little in children. One study found that patients with T1D had elevated levels of intercellular adhesion molecule (ICAM), nitric oxide (NO), and malondialdehyde (MDA) when compared to healthy controls, and those with poor glycemic control also had higher levels of vascular endothelial growth factor (VEGF; Seckin et al., [@B41]).

One routine measurement that is used to screen for nephropathy may have a new role in predicting CVD risk: urine microalbumin. Adult studies have shown 24 h urine albumin levels to predict increased risk for CVD in both patients with T1D and T2D (Deckert et al., [@B12]; Miettinen et al., [@B31]; Zhan et al., [@B50]). While it is exciting to think of the possibility of using one tool to screen for two common complications of DM, little is known about the predictive value of microalbuminuria for CVD in the pediatric population.

Cholesterol Algorithm
=====================

At the UNC, Division of Pediatric Endocrinology, we have compiled the major guidelines and consensus statements regarding dyslipidemia management in pediatric patients with DM into an algorithm designed to help our providers practically apply the latest recommendations regarding lipid screening and treatment (see Figure [1](#F1){ref-type="fig"}). We are in the process of collecting data to evaluate its effectiveness. The algorithm underwent review by the UNC Pediatric Endocrinology Division members prior to implementation and has been approved by the Division for use in the UNC Pediatric Endocrinology diabetes clinic.

![**University of North Carolina-Chapel Hill pediatric endocrinology cholesterol algorithm**.](fendo-02-00047-g001){#F1}

Of note, our screening interval for patients with T2D who have a history of normal lipids is based on the ADA's guidelines from 2003, because we felt that their high prevalence of comorbidities and increased risk for CVD warrants closer monitoring of lipids. Our initial screen is a non-FLP (TC, HDL-C, and non-HDL-C) because most of our patients do not come to appointments fasting. If our patients have been fasting for more than 8 h, we begin with a FLP (TC, LDL, TG, HDL-C). We rely on the UNC laboratory reference range for distinguishing normal from abnormal values for non-FLPs. These ranges may differ at other institutions. We rescreen patients with normal non-FLPs the same as the 2003 ADA recommended screening intervals for patients with normal FLPs. If the non-FLP is abnormal, we then arrange a FLP for further evaluation. Our algorithm is then based on the 2011 ADA guidelines unless a different set of guidelines addresses a topic not addressed by the 2011 ADA guidelines. Because there has been little guidance besides lifestyle modifications in the approach to improving low HDL-C or elevated TG levels, we have not addressed these cholesterol derangements in our algorithm. Our diabetes care providers have felt that this tool has been a useful reference for when to screen for and how to treat dyslipidemia in the UNC pediatric diabetes population.

Conclusion
==========

Cholesterol screening is not universal among pediatricians, and despite compelling data that pediatric patients with DM are at increased risk for CVD, clinicians often do not feel comfortable prescribing dyslipidemic medications because of concerns for long-term medication safety. Additionally, there is no longitudinal data to show that early dyslipidemia treatment improves CVD outcome. One prescription claims data study of commercially insured children in the United States from 2004 to 2007 showed that the prevalence of dyslipidemia medication prescriptions was 0.2 per 1000 youths, of which statins accounted for 56.9%. During the study period, dyslipidemia prescription claims dropped by 14--20% overall except in 16--18 year old females whose use increased by 14%; however, insurance claims for statins decreased by 22.9% overall (Liberman et al., [@B26]).

Current clinical guidelines addressing dyslipidemia in youth with DM have been derived from expert opinions or extrapolated from the adult literature. There are limited recommendations regarding treatment of high TG or low HDL-C, and the most current guidelines do not clearly delineate any differences in the approach to pediatric T1D versus T2D. Because recent studies have revealed a greater number of CVD risk factors in youth with T2D compared to those with T1D, guidelines for pediatric T2D may need to be more aggressive.

Further studies are needed to evaluate the long-term safety and effectiveness of statins and other cholesterol-lowering medications in children with DM, and to determine whether early treatment significantly reduces CVD in adulthood. Additional research is also needed to explore the clinical usefulness of various biomarkers and radiographic measurements. Though the optimal approach to managing dyslipidemia in pediatric patients with DM remains unclear, it can be confidently stated that they are at high risk for CVD, and we, as the medical and scientific community, must strive to find the optimal prevention, screening, and treatment regimen.
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